A phase Ib/II clinical trial testing the combination of BYL719 and an anti-IGF1R antibody, AMG479, showed toxicity in cancer patients (NCT 01708161), but there are also other approaches to targeting the IGF2/IGF1R axis. Here, IGF2 is linked to cancer.